Video

Dr. Olin on FLT3 Inhibitor Research in AML

Author(s):

Rebecca L. Olin, MD, MSCE

In Partnership With:

Rebecca L. Olin, MD, MSCE, discusses research surrounding FLT3 inhibitors as a treatment for patients with acute myeloid leukemia.

Rebecca L. Olin, MD, MSCE, associate professor, Department of Medicine (Hematology/Oncology), Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses research surrounding FLT3 inhibitors as a treatment for patients with acute myeloid leukemia.

Midostaurin (Rydapt) in combination with 7+3 has become the standard of care in patients with FLT3-positive disease at diagnosis due to the overall survival benefit that was seen in the RATIFY trial, explains Olin. Gilteritinib (Xospata) is a different type of FLT3 inhibitor, which was looked at in the relapsed/refractory setting and compared with standard chemotherapy. Results showed that when gilteritinib is given as monotherapy, it leads to a significant improvement in response rate and survival, thereby making it a reasonable standard of care in the second-line setting, says Olin.

These agents will be examined in the maintenance setting, as well. There are already some data on sorafenib (Nexavar) and midostaurin in the maintenance setting, and an ongoing trial is also examining gilteritinib as a maintenance option, according to Olin.

Related Videos
Aditya Bardia, MD, MPH, FASCO
Christina S. Baik, MD, MPH
Dana Zakalik, MD
David C. Fisher, MD
Kevin Kalinsky, MD, MS
Alberto Montero, MD, MBA, CPHQ
R. Lor Randall, MD, FACS
Daniel E. Haggstrom, MD
Jairam Krishnamurthy, MD, FACP
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Related Content
Leukemia
November 6th 2024

NICE Advocates Reimbursement for Avapritinib in Aggressive Systemic Mastocytosis, Other Hematologic Malignancies

Jennie W. Taylor, MD, MPH, associate professor, clinical neurology, University of California, San Francisco, community engagement liaison, Neurologic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
October 10th 2024

FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.
November 2nd 2024

The OncFive: Top Oncology Articles for the Week of 10/27

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Hope Rugo, MD, FASCO, of UCSF Helen Diller Family Comprehensive Cancer Center
October 31st 2024

Inavolisib Regimen Approval Opens the Door for Triplet Therapies in HR+, HER2– Breast Cancer

Maurie Markman, MD, of City of Hope
October 30th 2024

Precision Medicine Unfolds in Oncology, Bearing Substantial Implications for the Future